Impella Cardiosystems

What Impella Cardiosystems does

Impella Cardiosystems develops, manufactures, and markets minimally invasive cardiovascular support systems, with its flagship product being the Impella CP with SmartAssist percutaneous heart pump. The device is the only U.S. FDA-approved catheter-based heart pump indicated for patients with severe coronary artery disease undergoing high-risk percutaneous coronary intervention (PCI), temporarily taking over cardiac pumping function to maintain blood flow to vital organs while interventional cardiologists perform stenting or atherectomy. The technology is inserted through a small puncture in the femoral artery and guided to the left ventricle, enabling what the company brands as the Protected PCI procedure. Clinical evidence from the PROTECT II randomized trial demonstrates that 8-in-10 patients experience heart function improvement or symptom reduction within 90 days of the procedure, and over 400,000 patients have been supported with Impella devices cumulatively.

The company's primary customers are hospitals and healthcare systems with cardiac catheterization laboratories, accessed through a field sales force targeting interventional cardiologists in a B2B2C model. Revenue is generated through hardware sales of single-use Impella devices per procedure, with pricing negotiated through hospital procurement channels. Distribution is currently concentrated in the United States, with educational outreach segmented across multiple patient demographics including women, African American communities, and younger populations. Following Johnson & Johnson's 2022 acquisition of parent entity ABIOMED for approximately $16.6 billion, Impella now operates within J&J's MedTech segment, leveraging global commercial infrastructure and the HeartRecovery.com professional education platform to drive clinical adoption.

Name

Impella Cardiosystems

Legal name

ABIOMED

Website

https://impella.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

1–10 employees

Short description

Impella Cardiosystems develops FDA-approved percutaneous heart pumps used during high-risk PCI procedures to maintain blood flow in patients with severe coronary artery disease, serving hospitals with cardiac catheterization labs through a B2B2C model.

Ownership category

akta.pro rank

Product category

Percutaneous Ventricular Assist Devices (Circulatory Support)

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG)

akta.pro secondary industries

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB), Cardiac Assist & Heart Failure Therapies (Implantables, Neuromodulation) (HLAHAFAL)

Keywords

• Percutaneous heart pumps
• Cardiovascular support systems
• Minimally invasive cardiac devices
• High-risk PCI support
• Heart recovery technology

Headquarters

HQ city

Aachen

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Impella Heart Pump Device Sales: Impella generates revenue through the sale of its Impella heart pump devices to hospitals and healthcare systems. The devices are used during Protected PCI procedures and are typically removed after the procedure, making this a recurring procedural revenue model where hospitals purchase devices for each procedure performed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Impella Cardiosystems develops, manufactures, and markets the Impella platform of minimally invasive percutaneous heart pumps used during high-risk percutaneous coronary intervention (PCI) procedures. Its flagship Impella CP with SmartAssist is an FDA-approved catheter-based pump that temporarily takes over the heart's pumping function to maintain blood flow to vital organs while interventional cardiologists perform stenting or atherectomy, enabling heart recovery in patients with severe coronary artery disease.

Product overview

Impella Cardiosystems offers a focused portfolio centered on the Impella heart pump platform. The primary product is the Impella CP with SmartAssist, an FDA-approved percutaneous heart pump used during Protected PCI procedures. This catheter-based device temporarily assists heart function, maintaining blood flow to critical organs while physicians perform stenting or atherectomy procedures. The Impella platform is specifically indicated for high-risk PCI patients and has supported over 400,000 patients. Clinical data shows 8-in-10 patients treated with Impella heart pumps experience reduction in heart failure symptoms or improvement in heart function within 90 days after the procedure.

Differentiator

Problem solved

Functional benefit

Brands

• Impella CP: FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk PCI
• Impella CP with SmartAssist
• Protected PCI
• SmartAssist

Products and services

• Impella CP with SmartAssist FDA-approved percutaneous heart pump that temporarily takes over the pumping function of the heart to maintain blood flow to vital organs during high-risk percutaneous coronary intervention (PCI) procedures such as stenting and atherectomies. It is sold to hospitals and cardiac catheterization labs for use by interventional cardiologists performing "Protected PCI" in patients with severe coronary artery disease or advanced heart failure.

Quantifiable outcome

• 8-in-10 patients experienced reduction in heart failure symptoms or improvement in heart function within 90 days after Protected PCI procedure
• +3 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Teleflex: Teleflex manufactures the Arrow Intra-Aortic Balloon Pump (IABP), the principal percutaneous mechanical circulatory support alternative to Impella for high-risk PCI and cardiogenic shock, making it the closest direct competitor in Cath-Lab hemodynamic support devices.
• Getinge: Getinge (via Maquet) sells the Cardiohelp ECMO system and IABP consoles used for mechanical circulatory support during high-risk PCI and cardiogenic shock, directly competing with Impella in temporary mechanical support for cardiac cath labs and ICU teams.
• LivaNova: LivaNova previously commercialized the TandemHeart percutaneous ventricular assist system, a direct mechanical circulatory support competitor to Impella, and continues to serve the cardiopulmonary and circulatory support markets where Impella operates.

Broad incumbents

• Medtronic: Medtronic is a diversified cardiovascular incumbent with legacy mechanical support products (including Affinity IABP and ECMO partnerships) and a broad interventional cardiology portfolio that overlaps the Cath-Lad customer ecosystem served by Impella.
• Terumo: Terumo sells ECMO systems, oxygenators, and percutaneous catheter products used in cardiovascular support, positioning it as a broad incumbent competing in the mechanical circulatory support and interventional cardiology spaces where Impella is deployed.
• Abbott: Abbott is a major interventional cardiology incumbent (XIENCE stents, coronary diagnostics) and supplies CentriMag surgical VADs; it shares Cath-Lab customer relationships with Impella and competes in adjacent cardiovascular device categories.
• Boston Scientific: Boston Scientific is a leading interventional cardiology incumbent (coronary stents, Intravascular imaging) serving the same Cath Lab operators who purchase Impella pumps, representing an overlapping channel and customer base even where mechanical support is not in its core portfolio.
• Edwards Lifesciences: Edwards Lifesciences is a structural heart and critical care incumbent (surgical heart valves, transcatheter valves, pressure monitoring) that serves interventional cardiologists and cardiac surgeons in the same hospital systems purchasing Impella devices.
• Nipro: Nipro manufactures IABP catheters and ECMO-related circulatory support devices marketed globally, positioning it as a regional and adjacent incumbent competing in the same mechanical circulatory support category as Impella.

Emerging players

• Magenta Medical: Magenta Medical is an emerging player developing a next-generation percutaneous ventricular assist device (pVAD) for high-risk PCI and cardiogenic shock - the same indications where Impella has regulatory exclusivity and clinical installed base - and represents a focused future entrant.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/protectedpci
• Facebookfacebook.com/protectedpci
• LinkedInlinkedin.com/company/protected-pci

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Impella Cardiosystems